Eli Lil­ly to buy ra­dio­phar­ma com­pa­ny Point Bio­phar­ma for $1.4B as PhI­II read­out looms

On a deal­mak­ing spree, Eli Lil­ly will buy an­oth­er can­cer biotech, this time swoop­ing in for pub­licly trad­ed ra­dio­phar­ma com­pa­ny Point Bio­phar­ma in a cash ac­qui­si­tion worth about $1.4 bil­lion.

Lil­ly’s ad­di­tion of a ra­dio­phar­ma­ceu­ti­cal com­pa­ny comes as the space heats up with new star­tups, a re­cent IPO from Rayze­Bio and high de­mand for No­var­tis’ Plu­vic­to. The Big Phar­ma is mov­ing in on Point as it an­tic­i­pates late-stage clin­i­cal da­ta in the near term, with two ra­di­oli­gand can­cer ther­a­pies in Phase III de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER